Johanna G. van der Bom

Author

Also Known As

Bom, van der, J.G., Bom, J.G. van der, Eveline Mauser-Bunschoten, F.R. Rosendaal, I Van Kamp, J G van der Bom, J G. van der Bom, J Van Der Bom, J. Bom, J. G. VAN DER BOM

452

Publications

15.3K

Citations

H-Index

151

Concepts

All Affiliations

Leiden University Medical Center University Medical Center Utrecht Sanquin Jon J van Rood Centre for Clinical Transfusion Research Erasmus MC

About

Johanna G. van der Bom is an author at Leiden University Medical Center specializing in medicine, hematology, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	56	2.8K
2	Public Health	24	27	1.8K
3	Health Sciences	14	15	708
4	Allergy	4	4	193
5	Blood Transplantation	3	3	129

Johanna G. van der Bom

192

Publications

12.1K

Citations

H-Index

Page 1

	Year	Citations
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study Samantha C. Gouw, Johanna G. van der Bom, H. Marijke van den Berg Blood	2007	484
Factor VIII Products and Inhibitor Development in Severe Hemophilia A Samantha C. Gouw, Johanna G. van der Bom, Rolf Ljung, New England Journal of Medicine	2013	431
Bleeding in carriers of hemophilia Iris Plug, Eveline P. Mauser‐Bunschoten, Annette Bröcker‐Vriends, Blood	2006	361
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study Samantha C. Gouw, H. Marijke van den Berg, Kathelijn Fischer, Blood	2013	319
Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study Iris Plug, Johanna G. van der Bom, Marjolein Peters, Journal of Thrombosis and Haemostasis Clinical EpidemiologyHematologyBleeding DisorderPublic HealthEpidemiology	2006	278
The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia Kathelijn Fischer, Johanna G. van der Bom, Eveline P. Mauser‐Bunschoten, Blood	2002	257
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study Samantha C. Gouw, Johanna G. van der Bom, Günter Auerswald, Blood	2007	236
Risk factors and time delay associated with cardiac device infections: Leiden device registry Jaco C Lekkerkerker, Cees van Nieuwkoop, Serge A. Trines, Heart	2008	231
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters, Blood	2013	214
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels I. E. M. DEN UIJL, Kathelijn Fischer, Johanna G. van der Bom, Haemophilia	2010	209

Page 1